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CD341 CELLS FROM POOR MOBILIZERS ARE QUALITATIVELY EQUIVA-
LENT TO CD341 CELLS FROM GOOD MOBILIZERS
Jiang, L.1, Malik, S.1, Litzow, M.2, Gastineau, D.2, Micallef, I.2,
Roy, V.3, Solberg, L.3, Zubair, A.C.1 1Mayo Clinic, Jacksonville, FL;
2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL
Marrow damage from chemo- and radiation therapy can lead to
poor CD341 cell mobilization. Such therapies have also been sug-
gested to affect quality of CD341 cells. We tested the hypothesis
that CD341 cells from low mobilizers are qualitatively inferior to
CD341 cells from high mobilizers.
CD341 cell quality was defined by proportion of primitive
CD341 cell subsets (CD341CD38-, CD341HLA-DR- and
CD341 in G0 stage of cell cycle), the proportion of CD341 cells
that express CXCR4 and CD26 homing proteins and days to neutro-
phil and platelet engraftments post transplant. CD341 cell content
and CD34 subsets analyses were performed using flow cytometry.
Cell cycle analysis was performed using simultaneous staining of
DNA (Hoechst) and RNA (Pyronin Y) to distinguish CD341 cells
in G0, G1 and S/M phases of cell cycle.
Weevaluated theCD341 cell quantityandqualityof139autologous
filgrastimmobilized HPC products collected between 2004 and 2007.
The median patient age was 58 years and 60% were males. Patients
were diagnosed with plasma cell dyscrasia, or non-Hodgkin’s lym-
phoma. The median CD341 cell/kg was 4.9  106 and median time
to neutrophil and platelet engraftmentwas 12 and 18 days respectively.
Patients were grouped into low, moderate and high mobilizers if
their total CD341 cell collection was # 3  106/kg, . 3 106/kg
and\5106/kg, and$ 5 106/Kg respectively. The median num-
ber of primitive stem cells increases with increasing CD341 cell
numbers and this association was statistically significant (p 5
0.001). However, when the ratios of the primitive CD34 subsets to
total CD341 cell counts were compared among the mobilization
groups, the ratios were not significantly different. Co-expression of
neither CD26 nor CXCR4 homing proteins with CD34 antigen cor-
related with CD341 cell mobilization.
Table 1. CD34+ cell subsets and mobilization capacity
Mobilization (median  106/Kg)CD34+ subsets Low Moderate High p valueN 33 70 36CD34+ 3 4.6 6.6 <0.001CD34+CD38- 1.2 2.6 3.8 <0.001CD34+HLA-DR- 1.1 1.6 2 0.001CD34+CD26+ 0 0 0 0.88CD34+CXCR4+ 0 0 0 0.55CD34+G0 stage 1.5 3.3 4.6 <0.001CD34+ subsets/CD34+ ratioCD34+CD38- 0.52 0.55 0.53 0.41CD34+HLA-DR- 0.30 0.35 0.27 0.84CD34+G0 stage 0.71 0.75 0.64 0.58Evaluation of days to neutrophil engraftment among the mobiliza-
tion groups did not show a statistically significant difference (p 5
0.1). However, days to platelet engraftment among the mobilization
groups was statistically significantly different (p 5 0.05). This find-
ing may not be clinically significant.
In summary, the proportion of primitiveCD341 cells inHPCprod-
ucts anddays toneutrophil engraftmentwerenot influencedbyCD341
cell mobilization capacity. The quality of CD341 cells from low
mobilizerswas comparable toCD341 cells fromhighmobilizers. Prior
therapies may affect the quantity but not the quality of CD341 cells.137
CYCLOPHOSPHAMIDE (CY)/G-CSF CANNOT COMPLETELY OVERCOME
IMID-INDUCED IMPAIRMENT OF PERIPHERAL BLOOD STEM CELL (PBSC)
MOBILIZATION (MOB) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
Osman, S., Kanate, A., Bunner, P., Leadmon, S., Hart, K., Goff, L.,
Tse, W., Cumpston, A., Remick, S., Abraham, J., Craig, M.,
Hamadani, M. West Virginia University Hospitals, Morgantown, WVNovel agents are routinely used as induction therapy for MM, but
there is concern about their impact on PBSC Mob. Some studies
suggest that CY/G-CSF Mob may overcome suppressive effects of
lenalidomide on PBSCMob, however an optimal mobilization strat-
egy for this population remains controversial.
We report here PBSC collection outcomes of 107 consecutive
MM patients, who uniformly underwent Mob with CY (1.5mg/m2)
and G-CSF (10mg/kg/day). 44 patients received older induction
therapies, while 63 received novel agents (including; lenalidomide-
(n5 13), bortezomib- (n 5 15) and IMiD- (n5 49) containing reg-
imens). Mob parameters including, peak peripheral blood (PB)
CD341 count, CD341 cell yield on day1, total CD341 cell yield,
and number of apheresis sessions were analyzed relative to induction
regimens. Mobilization failure was defined as failure to collect$ 2
106 cells/Kg body weight.
The median patient age was 57yrs. The median number of prior
therapies was one, while 29% received prior radiation. Compared to
older regimens, patients receiving novel inductions had lower peak
PB CD341 count (70/uL vs. 47/uL; p 5 0.003), however total
CD341 cell yield (7.6  106 vs. 6.4  106; p 5 0.07), CD341 dose
collected on day 1 (3.9 106 vs 3.1 106 p5 0.20) and total number
of apheresis sessions (2.6 vs 2.2 p 5 0.068) were not significantly dif-
ferent. Lenalidomide containing regimens when compared to all other
regimens (n5 94) revealed a lower peak PB CD341 count (34/uL vs
59/uL; p5 0.03) and higher total number of apheresis sessions (3.3 vs
2.3; p5 0.001). Total CD341 yield (6.8 106 vs 7.1 106 p5 0.78)
and CD341 cells collected on day 1 (2.6 106 vs 3.7 106; p5 0.24)
were not significantly different. IMiDs as a class when compared to
non-IMiD regimens showed significantly lower peak PB CD341
count (45/uL vs 66/uL; p 5 0.004) and higher number of apheresis
sessions (2.7 vs 2.2; p 5 0.004). Total CD341 yield (7.6  106 vs
6.7  106 p 5 0.21) and dose collected on day 1 (3.5  106 vs 3.6 
106; p 5 0.91) were not significantly different. A total of 6 patients
failed mobilization, including 3 who received lenalidomide.
In conclusion our limited retrospective study shows that CY/G-
CSF Mob partially overcomes suppressive effects of lenalidomide
on PBSC mobilization by requiring increased number of apheresis
sessions. Our data also suggest that impairment of PBSCMobmight
be a class-effect of IMiDs, and not merely restricted to lenalidomide,
at least in the context of CY/G-CSF Mob.138
THE EFFECT OF BODY MASS INDEX ON PATIENT MORTALITY AFTER
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jones, J.L., Hundley, B.C., Salzman, D.E., Koralkar, R., Vaughan,W.P.
University of Alabama at Birmingham, Birmingham, AL
Background: Elevated body mass index (BMI) is associated with
lifelong risk of medical morbidity and has been implicated as a risk
factor for mortality after hematopoietic stem cell transplantation
HSCT. Previous publications suggest various thresholds for in-
creased mortality. The Center for International Bone Marrow
Transplant Research (CIBMTR) threshold for considering obesity
a significant comorbidity is a BMI greater than 35. A recent publica-
tion using CIBMR data suggested a BMI of 30 was a significant
threshold for morbidity and mortality.
Objective:To further investigate the association of BMI with excess
mortality in a single center analysis, we undertook a survey of 232
consecutive autologous HSCT (aHSCT) patients with myeloma
and non-Hodgkin’s lymphoma.
Patients and Methods: These 232 adult patients studied received
their aHSCT at UAB between November 2006 and September
2010. Height and weight were obtained during the final evaluation
and consent visit just prior to initiation of preparative therapy, ex-
cluding 10 patients with missing one or the other of these variables.
Myeloma patients received melphalan 200mg/ M2 (reduced to
140mg/M2 for age greater than 70 or creatinine clearance \
40mL/min). Non-Hodgkin’s lymphoma (NHL) patients received
intravenous busulfan targeted to a total exposure of 16000mM*min,
cyclophosphamide (5gm/M2) and etoposide (1800 mg/M2). Based
upon the reviewed literature, we defined obesity using three BMI co-
horts: non-obese\35kg/M2, obese5 35-39kg/M2, morbidly obese
